[1]
|
Yang, X., et al. (2017) The Optimal First-Line Treatment for Advanced Thymic Carcinomas. Journal of Thoracic On-cology, 12, S2061. https://doi.org/10.1016/j.jtho.2017.09.1083
|
[2]
|
Eng, T.Y., et al. (2004) Thymic Carcinoma: State of the Art Review. International Journal of Radiation Oncology Biology Physics, 59, 654-664. https://doi.org/10.1016/j.ijrobp.2003.11.021
|
[3]
|
Kurup, A. and Loehrer, P.J. (2004) Thymoma and Thymic Car-cinoma: Therapeutic Approaches. Clinical Lung Cancer, 6, 28-32. https://doi.org/10.3816/CLC.2004.n.018
|
[4]
|
Litvak, A.M., et al. (2014) Clinical Characteristics and Outcomes for Patients with Thymic Carcinoma: Evaluation of Masaoka Staging. Journal of Thoracic Oncology, 9, 1810-1815. https://doi.org/10.1097/JTO.0000000000000363
|
[5]
|
Thomas, A., et al. (2015) Sunitinib in Patients with Chemo-therapy-Refractory Thymoma and Thymic Carcinoma: An Open-Label Phase 2 Trial. The Lancet Oncology, 16, 177-186. https://doi.org/10.1016/S1470-2045(14)71181-7
|
[6]
|
Yokoyama, S., et al. (2016) Prognostic Value of Pro-grammed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma. Clinical Cancer Research, 22, 4727-4734. https://doi.org/10.1158/1078-0432.CCR-16-0434
|
[7]
|
Girard, N. (2014) Chemotherapy and Targeted Agents for Thymic Malignancies. Expert Review of Anticancer Therapy, 12, 685-695. https://doi.org/10.1586/era.12.29
|
[8]
|
Giaccone, G., et al. (2018) Pembrolizumab in Patients with Thymic Carci-noma: A Single-Arm, Single-Centre, Phase 2 Study. The Lancet Oncology, 19, 347-355. https://doi.org/10.1016/S1470-2045(18)30062-7
|
[9]
|
Cho, J., et al. (2018) Pembrolizumab for Patients with Re-fractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial. Journal of Clinical Oncology, 37, 2162-2170.
|
[10]
|
王凯瑞, 等. 胸腺上皮肿瘤中程序性死亡蛋白1及其配体的临床研究进展[J]. 现代肿瘤医学, 2020, 28(9): 1580-1582.
|
[11]
|
Ferris, R.L., et al. (2016) Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. New England Journal of Medicine, 375, 1856-1867. https://doi.org/10.1056/NEJMoa1602252
|
[12]
|
Postow, M.A., et al. (2015) Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma. New England Journal of Medicine, 372, 2006-2017. https://doi.org/10.1056/NEJMoa1414428
|
[13]
|
Reck, M., et al. (2016) Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. New England Journal of Medicine, 375, 1823-1833. https://doi.org/10.1056/NEJMoa1606774
|
[14]
|
Motzer, R.J., et al. (2015) Nivolumab versus Everolimus in Ad-vanced Renal-Cell Carcinoma. New England Journal of Medicine, 373, 1803-1813. https://doi.org/10.1056/NEJMoa1510665
|
[15]
|
Takashi Kojima, M., et al. (2020) Randomized Phase III KEYNOTE-181 Study of Pembrolizumab versus Chemotherapy in Advanced Esophageal Cancer. Journal of Clinical Oncology, 38, 4138-4148.
https://doi.org/10.1200/JCO.20.01888
|
[16]
|
Keir, M.E., et al. (2008) PD-1 and Its Ligands in Tolerance and Im-munity. Annual Review of Immunology, 26, 677-704.
https://doi.org/10.1146/annurev.immunol.26.021607.090331
|
[17]
|
Sharpe, A.H., et al. (2007) The Function of Pro-grammed Cell Death 1 and Its Ligands in Regulating Autoimmunity and Infection. Nature Immunology, 8, 239-245. https://doi.org/10.1038/ni1443
|
[18]
|
Okazaki, T. and Honjo, T. (2007) PD-1 and PD-1 Ligands: From Discovery to Clinical Application. International Immunology, 19, 813-824. https://doi.org/10.1093/intimm/dxm057
|
[19]
|
Nurieva, R.I., Liu, X. and Dong, C. (2009) Yin-Yang of Costimulation: Crucial Controls of Immune Tolerance and Function. Immunological Reviews, 229, 88-100. https://doi.org/10.1111/j.1600-065X.2009.00769.x
|
[20]
|
Francisco, L.M., Sage, P.T. and Sharpe, A.H. (2010) The PD-1 Pathway in Tolerance and Autoimmunity. Immunological Reviews, 236, 219-242. https://doi.org/10.1111/j.1600-065X.2010.00923.x
|
[21]
|
Katsuya, Y., et al. (2015) Immunohistochemical Status of PD-L1 in Thymoma and Thymic Carcinoma. Lung Cancer, 88, 154-159. https://doi.org/10.1016/j.lungcan.2015.03.003
|
[22]
|
Giaccone, G. and Kim, C. (2021) Durable Response in Patients with Thymic Carcinoma Treated with Pembrolizumab after Prolonged Follow-Up. Journal of Thoracic Oncology, 16, 483-485. https://doi.org/10.1016/j.jtho.2020.11.003
|
[23]
|
Katsuya, Y., et al. (2019) Single-Arm, Multicentre, Phase II Trial of Nivolumab for Unresectable or Recurrent Thymic Carcinoma: PRIMER Study. European Journal of Cancer, 113, 78-86. https://doi.org/10.1016/j.ejca.2019.03.012
|
[24]
|
Sakane, T., et al. (2018) A Comparative Study of PD-L1 Immunohistochemical Assays with Four Reliable Antibodies in Thymic Carcinoma. Oncotarget, 9, 6993-7009. https://doi.org/10.18632/oncotarget.24075
|
[25]
|
Katsuya, Y., et al. (2016) Expression of Programmed Death 1 (PD-1) and Its Ligand (PD-L1) in Thymic Epithelial Tumors: Impact on Treatment Efficacy and Alteration in Expression after Chemotherapy. Lung Cancer, 99, 4-10.
https://doi.org/10.1016/j.lungcan.2016.05.007
|
[26]
|
Weissferdt, A., et al. (2017) Expression of PD-1 and PD-L1 in Thymic Epithelial Neoplasms. Modern Pathology, 30, 826-833. https://doi.org/10.1038/modpathol.2017.6
|
[27]
|
Chen, Y., et al. (2018) Correlation between the Expression of PD-L1 and Clinicopathological Features in Patients with Thymic Epithelial Tumors. BioMed Research International, 2018, Article ID: 5830547.
https://doi.org/10.1155/2018/5830547
|
[28]
|
Duan, J., et al. (2018) Impact of PD-L1, Transforming Growth Fac-tor-Beta Expression and Tumor-Infiltrating CD8(+) T Cells on Clinical Outcome of Patients with Advanced Thymic Epi-thelial Tumors. Thoracic Cancer, 9, 1341-1353.
https://doi.org/10.1111/1759-7714.12826
|
[29]
|
Funaki, S., et al. (2019) The Prognostic Impact of Programmed Cell Death 1 and Its Ligand and the Correlation with Epithelial-Mesenchymal Transition in Thymic Carcinoma. Cancer Medi-cine, 8, 216-226.
https://doi.org/10.1002/cam4.1943
|
[30]
|
Song, J.S., et al. (2019) Clinicopathologic Significance and Immunoge-nomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epi-thelial Tumors. Frontiers in Oncology, 9, 1055.
https://doi.org/10.3389/fonc.2019.01055
|
[31]
|
Rouquette, I., et al. (2019) Immune Biomarkers in Thymic Epithelial Tumors: Expression Patterns, Prognostic Value and Comparison of Diagnostic Tests for PD-L1. Biomarker Research, 7, Article No. 28.
https://doi.org/10.1186/s40364-019-0177-8
|
[32]
|
杨映红, 吴龙, 冯昌银, 黄建平. 胸腺鳞状细胞癌41例临床病理分析及PD-L1表达的意义[J]. 临床与实验病理学杂志, 2021, 37(10): 1227-1230.
|
[33]
|
Kashima, J., et al. (2022) CD70 in Thymic Squamous Cell Carcinoma: Potential Diagnostic Markers and Immunotherapeutic Targets. Frontiers in Oncology, 11, Article ID: 808396. https://doi.org/10.3389/fonc.2021.808396
|
[34]
|
Isshiki, T., et al. (2018) Suc-cessful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression. Case Reports in Oncology, 11, 688-692. https://doi.org/10.1159/000493187
|
[35]
|
Yang, P., et al. (2018) Response to Nivolumab as Salvage Therapy in a Patient with Thymic Carcinoma. Journal of Thoracic Oncology, 13, e36-e39. https://doi.org/10.1016/j.jtho.2017.10.022
|
[36]
|
Rajan, A., et al. (2019) Efficacy and Tolerability of An-ti-Programmed Death-Ligand 1 (PD-L1) Antibody (Avelumab) Treatment in Advanced Thymoma. Journal for Immu-noTherapy of Cancer, 7, 269.
https://doi.org/10.1186/s40425-019-0723-9
|
[37]
|
Cafaro, A., et al. (2020) Pembrolizumab in a Patient with Heavily Pre-Treated Squamous Cell Thymic Carcinoma and Cardiac Impairment: A Case Report and Literature Review. Frontiers in Oncology, 10, 1478.
https://doi.org/10.3389/fonc.2020.01478
|
[38]
|
Thomas, Q.D., et al. (2022) Pembrolizumab plus Chemotherapy in Metastatic Thymic Carcinoma: A Case Report. Frontiers in Oncology, 11, Article ID: 814544. https://doi.org/10.3389/fonc.2021.814544
|
[39]
|
Rajan, A., et al. (2021) The Role of Immunotherapy for Manage-ment of Advanced Thymic Epithelial Tumors: A Narrative Review. Mediastinum, 5, 23. https://doi.org/10.21037/med-20-62
|
[40]
|
Rajan, A. (2021) Immunotherapy for Thymic Cancers: A Convoluted Path toward a Cherished Goal. Journal of Thoracic Oncology, 16, 352-354. https://doi.org/10.1016/j.jtho.2020.12.007
|
[41]
|
Brahmer, J., et al. (2015) Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. New England Journal of Medicine, 373, 123-135. https://doi.org/10.1056/NEJMoa1504627
|
[42]
|
Borghaei, H., et al. (2015) Nivolumab versus Docetaxel in Ad-vanced Nonsquamous Non-Small-Cell Lung Cancer. New England Journal of Medicine, 373, 1627-1639. https://doi.org/10.1056/NEJMoa1507643
|